Printer Friendly
The Free Library
19,585,946 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Alcon Signs Contract with LCA-Vision for 75 ALLEGRETTO WAVE[R] Excimer Lasers.


LASIK LASIK laser-assisted in-situ keratomileusis.

LA·SIK
n.
Eye surgery in which the surface of the cornea is reshaped using a laser, performed to correct certain refractive disorders such as myopia.
 Chain Standardizes with High-End Technology Based on Study Results

HUENENBERG, Switzerland -- Alcon, Inc. (NYSE NYSE

See: New York Stock Exchange
: ACL See access control list.

1. ACL - Access Control List.
2. ACL - Association for Computational Linguistics.
3. ACL - A Coroutine Language.

A Pascal-based implementation of coroutines.

["Coroutines", C.D.
) announced today that its affiliate Alcon Laboratories, Inc. has signed a five year contract with LCA-Vision, Inc. (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
: LCAV LCAV Legal Community Against Violence (San Francisco, CA)
LCAV Logistics Support Center Customer Asset Visibility
). Under the contract, LCA LCA Life Cycle Assessment
LCA Saint Lucia (ISO Country code)
LCA Life Cycle Analysis
LCA Linux.conf.au (Australian Linux conference)
LCA Labor Condition Application
LCA Light Combat Aircraft
 will place ALLEGRETTO al·le·gret·to   Music
adv. & adj.
In a moderately quick tempo, usually considered to be slightly slower than allegro but faster than andante. Used chiefly as a direction.

n. pl.
 WAVE([R]) Eye-Q 400Hz excimer lasers in all of the company's 75 LasikPlus([R]) vision surgery centers by the end of the third quarter of 2009. The contract comes as part of a decision by LCA to standardize its laser surgery technology on two laser platforms based on the results of a clinical study.

"LasikPlus([R]) recently completed a contralateral contralateral /con·tra·lat·er·al/ (-lat´er-al) pertaining to, situated on, or affecting the opposite side.

con·tra·lat·er·al
adj.
, prospective, randomized ran·dom·ize  
tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es
To make random in arrangement, especially in order to control the variables in an experiment.
 study measuring surgical outcomes on a variety of excimer lasers, including the most recently FDA-approved laser, the ALLEGRETTO WAVE([R]) Eye-Q," said Steven C. Straus, chief executive officer of LCA-Vision. "The ALLEGRETTO WAVE([R]) Eye-Q excimer laser performed well on our evaluation criteria, leading to our decision to reduce our laser platforms from three to two and to expand our relationship with Alcon."

Conducted through cooperation between members of the LCA medical advisory board and an outside research consultant, the study compared the clinical outcomes of laser eye surgery on various lasers. Results demonstrated excellent clinical outcomes on the ALLEGRETTO WAVE([R]) Eye-Q excimer laser.

"We are excited about the positive results of this clinical trial, which led to this agreement and the opportunity it provides Alcon to expand our relationship with LCA-Vision," said Bill Barton, U.S. area president at Alcon. "The study validates the investment we made in WaveLight and clearly demonstrates the quality outcomes achieved by the Allegretto platform."

Alcon's ALLEGRETTO WAVE([R])Eye-Q excimer laser combines proprietary wavefront-optimized PerfectPulse Technology([R]), precise laser control and unparalleled speed for the most advanced laser technology in LASIK surgery. Alcon acquired the U.S. rights to the technology through the acquisition of assets Acquisition of assets

A merger or consolidation in which an acquirer purchases the selling firm's assets.
 from WaveLight AG in February of 2008.

About ALLEGRETTO WAVE([R]) Eye-Q

The Alcon ALLEGRETTO WAVE([R]) Eye-Q excimer laser, engineered by WaveLight AG, combines precision technology with excellent laser energy stability, high-quality components and reliability. Built with pioneering wavefront principles, the laser's PerfectPulse Technology([R]) is designed to control each laser pulse from its generation to the exact point where it contacts the cornea. The ALLEGRETTO WAVE([R]) Eye-Q Excimer laser platform is the fastest laser in the United States at 400Hz and aims to provide optimal LASIK results.

About Alcon

Alcon, Inc. is the world's leading eye care company, with sales of approximately $6.3 billion in 2008. Alcon, which has been dedicated to the ophthalmic industry for 60 years, researches, develops, manufactures and markets pharmaceuticals, surgical equipment and devices, contact lens care solutions and other vision care products that treat diseases, disorders and other conditions of the eye. Alcon is the majority shareholder of WaveLight AG. For more information on Alcon, Inc., visit the Company's web site at www.alcon.com.

Caution Concerning Forward-Looking Statements. This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995. Any forward- looking statements reflect the views of our management as of the date of this press release with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except to the extent required under the federal securities laws and the rules and regulations promulgated by the Securities and Exchange Commission, we undertake no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.
COPYRIGHT 2009 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Article Type:Clinical report
Date:Mar 10, 2009
Words:600
Previous Article:Research and Markets: France Whey and Lactose Market 2009.
Next Article:Research and Markets: Vietnam Tourism Industry Forecast to 2012.
Topics:

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles